

Urinary Angiotensinogen Could Be a Prognostic Marker of Renoprotection of Olmesartan in Metabolic Syndrome Patients.

Mizushige T, *et al. Int J Mol Sci.* 2016; 17(11). pii: E1800.

- A 24-week study was performed (24 patients) to demonstrate urinary angiotensinogen as a potential prognostic marker of renoprotective effects (reduced albuminuria) of olmesartan (5-40 mg/day) in patients with metabolic syndrome.
- **Olmesartan treatment decreased urinary albumin and urinary angiotensinogen significantly.**
 - It was observed that patients with higher values of urinary angiotensinogen prior to treatment had a significantly greater decline in urinary albumin compared to those with lower values.

Urinary angiotensinogen could be a prognostic marker of the albuminuria reduction effects of olmesartan in patients with metabolic syndrome.